In a phase I clinical trial evaluating the efficacy of CD19 CAR-T cells in refractory B-cell non-Hodgkin’s lymphoma (B-NHL), increased infiltration of TAMs with M2 phenotype was found to be negatively associated with remission status [18]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.